Innovation Funding Database
Choose Your Area of Innovation:
Advanced Materials & Manufacturing
Aerospace & Spacetech
Agtech & Foodtech
Artificial Intelligence & Machines Learning
Biotech
Cleantech & Climatetech
Cybersecurity
Defensetech & Dual-Use Tech
eXtended Reality
Healthtech
Medtech
Other Tech
Quantum & Photonics
Robotics & Autonomous Systems
Military Working Dog Whole Blood Product or Substitute - SBIR DHA26BZ01-NV001
Deadline: April 29, 2026 (Estimated)
Funding Award Size: $250K (Estimated)
Description: Develop a shelf-stable (≥3 years), thermally robust (-9°C to 60°C) canine whole blood product or oxygen-carrying substitute for Military Working Dogs to treat traumatic hemorrhage from point-of-injury through definitive care, improving oxygen delivery and survival without canine testing.
Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.
Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.
Funding Amount:
Est. $250,000
Deadline to Apply:
Est. April 29th, 2026.
Objective:
Develop a whole blood product or substitute to aid in hemorrhage control for Military Working Dogs (MWD) after battlefield injury that can be used near the point of injury (POI) and throughout the continuum of care to reduce morbidity and mortality.
Description:
This topic is in support of the DoD Working Dog Strategic Research Plan concerning solutions for bleeding control and coagulopathy support.1 The Military Working Dog (MWD) provides a unique and important service to the warfighter. MWDs serve as sentries, perform tracking and patrol, and are used for the detection of explosives. These activities come with a high risk of injury. Uncontrolled hemorrhage following traumatic injury accounts for over 45% of all MWD battlefield deaths2. The current standard of care for hemorrhage in the MWD is to provide immediate fluid therapy through the delivery of crystalloid fluids as the first-line treatment, which is then followed by a synthetic colloid or hypertonic saline. These treatments also require the administration of supplemental oxygen to maintain appropriate oxygen levels and for the survival of the MWD3. To improve their survival rates, the development of a shelf stable canine whole blood product or substitute is a critical priority
The goal of this topic is to develop a stable canine whole blood product and/or substitute (i.e. hemoglobin or polymer oxygen carriers), intended for canine use at both POI and throughout the continuum of care. The product should have a shelf-life of greater than 3 years and be thermal stable (-9℃ to 60℃) to ensure accessibility in operational environments. The product must primarily replicate the oxygen carrier characteristics of whole blood and demonstrate the ability to be used safely and effectively to treat blood loss following traumatic injury. This research topic does not support the use of canines for testing purposes. Any animal testing would require use of suitable animal models that would approximate the response of a canine.
Blood products derived from canine donors must be negative for canine red blood cell antigens DEA 1.1 and DEA 1.2. Donor animals must also be tested for blood borne diseases including canine brucellosis, hemobartonellosis, Borrelia burgdorferi (Lyme disease), Dirofilaria immitis (heartworm disease), Ehrlichia canis, Rocky Mountain spotted fever, Coccidioides immitis, Babesia canis, Babesia gibsoni, Mycoplasma haemocanis and plasma levels of von Willebrand factor. All donor animals must be current on immunizations for canine distemper, hepatitis, parainfluenza, leptospirosis, parvovirus, Bordatella, coronavirus and rabies virus as applicable.
Who will win?
If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.
Who is eligible to apply?
Any company that meets the following criteria:
For-profit company
U.S.-owned and controlled.
500 or fewer employees (including affiliates)
How Can BW&CO Help?
1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.
2) Proposal strategy and review.
3) Administrative & compliance support.
Request to talk with a member of our team by completing the form below:
Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II) - SBIR DHA26BZ01-DV005
Deadline: April 29, 2026 (Estimated)
Funding Award Size: $1.3 Million (Estimated)
Description: Funding to develop small-molecule antifungal compounds from existing libraries that show nanomolar activity against resistant fungi such as Candida auris, Aspergillus, Fusarium, and Mucorales while maintaining low human toxicity.
Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.
Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.
Funding Amount:
Est. $1.3 Million
Deadline to Apply:
Est. April 29th, 2026.
Objective:
This topic is intended for technology proven ready to move directly into Phase II and accepts Direct to Phase II proposals only. The proposed research will focus on identifying compounds with broad-spectrum activity against clinically relevant fungal pathogens while minimizing toxicity to humans. The primary objective is to identify a small molecule with fungicidal properties that are safe for human use, with FDA clearance.
Description:
Fungal infections represent a growing global health challenge, particularly among immuno-compromised individuals. Invasive fungal infections caused by pathogens such as Candida species, Aspergillus species, Fusarium species, and Mucor species are associated with high morbidity and mortality rates. Fungal infections are associated with 130k hospitalizations, 13 million outpatient visits, and result in a financial burden of $19 billion on the civilian health care sector. Fungal wound infections in particular are also growing challenge for the military. Despite the availability of antifungal agents, current treatments are often limited by toxicity, drug resistance, and narrow-spectrum activity. The emergence of multidrug-resistant fungal strains, such as Candida auris, has further exacerbated the need for novel antifungal therapies. Small molecules with antifungal properties offer a promising avenue for addressing these challenges. Their ability to target specific fungal pathways, combined with the potential for oral bioavailability and low manufacturing costs, makes them ideal candidates for therapeutic development. However, significant scientific and technical hurdles remain with the discovery and optimization of small molecules that are both effective against fungal pathogens and safe for human use. Qualified proposals should identify small molecules with antifungal properties from an existing library. These small molecules should be active against all of the following fungi: Fusarium species, Aspergillus species, Candida auris, or Mucorales species. Qualified molecules will have antifungal activity at nanomolar concentrations. Further, these small molecules must have a cytotoxicity profile similar, or better than Amphotericin B.
Who will win?
If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.
Who is eligible to apply?
Any company that meets the following criteria:
For-profit company
U.S.-owned and controlled.
500 or fewer employees (including affiliates)
How Can BW&CO Help?
1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.
2) Proposal strategy and review.
3) Administrative & compliance support.
Request to talk with a member of our team by completing the form below:
Low-Cost, Phased Array Antennas for Collaborative Jamming in sUAS Swarms - SBIR Topic DAF26TZ01-NV004
Deadline: April 29, 2026 (Estimated)
Funding Award Size: $140,000 (Estimated)
Description: SBIR funding for small businesses to develop low-cost phased array antennas and signal processing techniques enabling collaborative electronic warfare using swarms of small unmanned aerial systems (3–7 units).
Disclaimer:
This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn.
Sign up below to be notified as soon as this topic is released again. In the meantime, we’d recommend you start planning to respond if within your capabilities.
Funding Amount:
Est. $140,000
Deadline to Apply:
Est. April 29th, 2026.
Objective:
Develop a low-cost, phased array antenna system and associated signal processing techniques for collaborative jamming applications using small to medium-sized sUAS swarms (3-7 units).
Description:
This topic addresses the need for affordable and scalable jamming capabilities leveraging sUAS swarms. Instead of focusing on individual, high-power jammers, this STTR seeks to develop a collaborative jamming approach using multiple sUAS equipped with low-cost phased array antennas.
The key innovation is the development of a low-cost phased array antenna system that can be precisely controlled to focus jamming energy on specific targets. By coordinating the signals from multiple sUAS in a swarm, the effective jamming power can be significantly increased. The focus on low to medium-sized swarms (3-7 units) allows for manageable coordination and control strategies.
This approach offers several advantages over traditional jamming techniques, including:
Increased jamming effectiveness through beamforming.
Improved resilience through redundancy.
Reduced risk of detection and counter-attack.
Lower cost compared to high-power jamming systems.
Who will win?
If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply.
Who is eligible to apply?
Any company that meets the following criteria:
For-profit company
U.S.-owned and controlled.
500 or fewer employees (including affiliates)
How Can BW&CO Help?
1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support.
2) Proposal strategy and review.
3) Administrative & compliance support.
Request to talk with a member of our team by completing the form below: